Figure 2. Antitumor effects of HER-2 peptide mimics are comparable to that of paclitaxel and trastuzumab. Female Fvbn mice (n = 5) were treated intravenously with HER-2 peptide mimics, paclitaxel or trastuzumab. Mice were treated weekly from week 4 to 10 and tumor volume was measured twice weekly. All mice were sacrificed at week 11 and tumors extracted and weighed. All treatments significantly inhibited tumor growth with a p value of < 0.001 (A) and the effect was also evident on normalized tumor weight (B). Error bars represent standard deviations from the mean.